View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 10, 2011

Pfizer’s Lipitor Awarded Six-Month Exclusivity Extension

The EU has extended Pfizer's exclusive rights to sell cholesterol-lowering drug Lipitor until May 2012 in a deal that could earn it $800m. The US pharmaceutical company will, in exchange, provide a modified form of the drug to a few thousand children, reports the Financial Times

By cms admin

The EU has extended Pfizer’s exclusive rights to sell cholesterol-lowering drug Lipitor until May 2012 in a deal that could earn it $800m.

The US pharmaceutical company will, in exchange, provide a modified form of the drug to a few thousand children, reports the Financial Times.

In November, Pfizer will launch a chewable, grape-flavoured, low-dose version of Lipitor in the EU, the same time its patents were due to expire.

Pfizer has sought a supplementary protection certificate in most EU countries, extending its monopoly over supplies and pricing of Lipitor.

Lipitor is primarily prescribed to adults with high levels of cholesterol, but is also given to a small number of children who have an inherited condition called familial hypercholesterolaemia, estimated to affect one in every 500 caucasians.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology